<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">18977324</PMID>
        <DateCompleted>
            <Year>2008</Year>
            <Month>11</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1878-3686</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Nov</Month>
                        <Day>04</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer cell</Title>
                <ISOAbbreviation>Cancer Cell</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Glycogen synthase kinase-3 and cancer: good cop, bad cop?</ArticleTitle>
            <Pagination>
                <MedlinePgn>351-3</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ccr.2008.10.013</ELocationID>
            <Abstract>
                <AbstractText>Dogma held that inhibition of the pleiotropic protein kinase glycogen synthase kinase-3 (GSK-3) was procarcinogenic due to its natural repression of beta-catenin. Now, Wang et al. have found the reverse in certain leukemias, possibly paving the way for small-molecule GSK-3 inhibitors as selective anticancer agents.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>Satish</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Samuel Lunenfeld Research Institute, Toronto, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Woodgett</LastName>
                    <ForeName>Jim</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>74711</GrantID>
                    <Agency>Canadian Institutes of Health Research</Agency>
                    <Country>Canada</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Cell</MedlineTA>
            <NlmUniqueID>101130617</NlmUniqueID>
            <ISSNLinking>1535-6108</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.26</RegistryNumber>
                <NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007938" MajorTopicYN="N">Leukemia</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">CAMS1555</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18977324</ArticleId>
            <ArticleId IdType="pii">S1535-6108(08)00336-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ccr.2008.10.013</ArticleId>
            <ArticleId IdType="pmc">PMC3006450</ArticleId>
            <ArticleId IdType="mid">CAMS1555</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12615961</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO J. 2005 Apr 20;24(8):1571-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15791206</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leukemia. 2006 Sep;20(9):1572-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16855632</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2006 Sep 1;12(17):5074-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16951223</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2008 Oct 30;455(7217):1205-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18806775</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Dev Cell. 2007 Jun;12(6):957-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17543867</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2007 Nov;7(11):823-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17957188</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Med Chem. 2008;15(15):1493-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18537625</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Res Rev. 2008 Sep;28(5):773-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18271054</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Genet Dev. 2007 Feb;17(1):45-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17208432</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
